Photo of Douglas I Lin,  MD, PhD

Douglas I Lin, MD, PhD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center

Douglas I Lin, MD, PhD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Assistant Professor, Pathology, Harvard Medical School
  • Staff Pathologist, Pathology, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am interested in developing novel screening tests, diagnostic tools and therapeutic options for gynecologic malignancies with a focus on endometrial and ovarian carcinomas. I am specifically interested in the identification of molecular and genetic alterations required in the development of ovarian and endometrial adenocarcinomas. The majority of ovarian and endometrial carcinomas are thought to be derived from precursor lesions, serous tubal Intraepithelial Carcinoma (STIC) and Endometrial Intrapithelial Neoplasia (EIN) respectively. Identification of novel early genetic alterations in the development of ovarian and endometrial carcinoma may be of therapeutic value and may aid in identification of patients who are at an increased risk of recurrence or metastasis following initial surgery and/or adjuvant chemo/radiation therapy.

Publications

Powered by Harvard Catalyst
  • Hecht JL, Lin DI, Garrett L. Endometrioid Tubal Intraepithelial Neoplasia (E-TIN) of the Fallopian Tube: A Case Series. Int J Gynecol Pathol 2019. PubMed
  • Lee J, Singh A, Ali SM, Lin DI, Klempner SJ. TNS1-ALK Fusion in a Recurrent, Metastatic Uterine Mesenchymal Tumor Originally Diagnosed as Leiomyosarcoma. Acta Med Acad 2019; 48:116-120. PubMed
  • Cahill LC, Fujimoto JG, Giacomelli MG, Yoshitake T, Wu Y, Lin DI, Ye H, Carrasco-Zevallos OM, Wagner AA, Rosen S. Comparing histologic evaluation of prostate tissue using nonlinear microscopy and paraffin H&E: a pilot study. Mod Pathol 2019. PubMed
  • Suster D, Ronen S, Peterson JF, Mackinnon AC, Hes O, Suster S, Lin DI. MDM2 amplification and immunohistochemical expression in sarcomatoid renal cell carcinoma. Hum Pathol 2019. PubMed
  • Tian K, Rubadue CA, Lin DI, Veta M, Pyle ME, Irshad H, Heng YJ. Automated clear cell renal carcinoma grade classification with prognostic significance. PLoS ONE 2019; 14:e0222641. PubMed
  • Ditzel HM, Strickland KC, Meserve EE, Stover E, Konstantinopoulos PA, Matulonis UA, Muto MG, Liu JF, Feltmate C, Horowitz N, Berkowitz RS, Gupta M, Hecht JL, Lin DI, Jochumsen KM, Welch WR, Hirsch MS, Quade BJ, Lee KR, Crum CP, Mutter GL, Nucci MR, Howitt BE. Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol 2018. PubMed
  • Xu J, Lin DI. Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas. PLoS ONE 2018; 13:e0199688. PubMed
  • Ta RM, Hecht JL, Lin DI. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors. Gynecol Oncol 2018; 151:401-406. PubMed
  • Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Ayhan A, Wood LD, Scharpf RB, Kurman R, Wang TL, Shih IM, Karchin R, Drapkin R, Velculescu VE. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun 2017; 8:1093. PubMed
  • Jones DH, Lin DI. Amplification of the NSD3-BRD4-CHD8 pathway in pelvic high-grade serous carcinomas of tubo-ovarian and endometrial origin. Mol Clin Oncol 2017; 7:301-307. PubMed
  • Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Miller VA, Agarwal N, Shuch B, Choueiri TK, Chung JH. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. Eur Urol 2017. PubMed
  • Lin DI, Chudnovsky Y, Duggan B, Zajchowski D, Greenbowe J, Ross JS, Gay LM, Ali SM, Elvin JA. Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type. Gynecol Oncol 2017; 147:626-633. PubMed
  • Yee EU, Hale G, Liu X, Lin DI. Hepatocellular Adenoma of the Placenta With Updated Immunohistochemical and Molecular Markers: A Case Report. Int J Surg Pathol 2016. PubMed
  • Lin DI, Hecht JL. Targeted Screening With Combined Age- and Morphology-Based Criteria Enriches Detection of Lynch Syndrome in Endometrial Cancer. Int J Surg Pathol 2016. PubMed
  • Pal SK, Choueiri TK, Wang K, Khaira D, Karam JA, Van Allen E, Palma NA, Stein MN, Johnson A, Squillace R, Elvin JA, Chmielecki J, Yelensky R, Yakirevich E, Lipson D, Lin DI, Miller VA, Stephens PJ, Ali SM, Ross JS. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. Eur Urol 2015. PubMed
  • Howitt BE, Hanamornroongruang S, Lin DI, Conner JE, Schulte S, Horowitz N, Crum CP, Meserve EE. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Am J Surg Pathol 2015; 39:287-93. PubMed
  • Winham WM, Lin D, Stone PJ, Nucci MR, Quick CM. Architectural versus nuclear atypia-defined FIGO grade 2 endometrial endometrioid adenocarcinoma (EEC): a clinicopathologic comparison of 154 cases with clinical follow-up. Int J Gynecol Pathol 2014; 33:120-6. PubMed
  • Nguyen PL,Lin DI,Lei J,Fiorentino M,Mueller E,Weinstein MH,Pagano M,Loda M. The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy. Urol Oncol 2009. PubMed
  • Barbash O, Zamfirova P, Lin DI, Chen X, Yang K, Nakagawa H, Lu F, Rustgi AK, Diehl JA. Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell 2008; 14:68-78. PubMed
  • Lin DI, Aggarwal P, Diehl JA. Phosphorylation of MCM3 on Ser-112 regulates its incorporation into the MCM2-7 complex. Proc Natl Acad Sci U S A 2008; 105:8079-84. PubMed
  • Lin DI, Lessie MD, Gladden AB, Bassing CH, Wagner KU, Diehl JA. Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis. Oncogene 2008; 27:1231-42. PubMed
  • Aggarwal P, Lessie MD, Lin DI, Pontano L, Gladden AB, Nuskey B, Goradia A, Wasik MA, Klein-Szanto AJ, Rustgi AK, Bassing CH, Diehl JA. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes Dev 2007; 21:2908-22. PubMed
  • Lin DI, Barbash O, Kumar KG, Weber JD, Harper JW, Klein-Szanto AJ, Rustgi A, Fuchs SY, Diehl JA. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol Cell 2006; 24:355-66. PubMed
  • Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 2006; 66:5723-8. PubMed
  • Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000; 157:1769-75. PubMed
Hide